Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis

Biogen Completes Acquisition of Apellis Pharmaceuticals

Thu, May 14, 2026 at 12:35 PM UTC 4 min read

Biogen has successfully completed its acquisition of Apellis Pharmaceuticals, a strategic move aimed at bolstering its portfolio in the neurology and ophthalmology sectors. This acquisition is significant for investors as it enhances Biogen's pipeline with Apellis' innovative therapies, potentially driving future revenue growth and market competitiveness. The integration of Apellis' assets could also lead to synergies that improve operational efficiency and expand Biogen's market reach.

Read full article →

Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key Metrics

Thu, May 7, 2026 at 8:00 PM UTC 4 min read

Apellis Pharmaceuticals (APLS) reported its Q1 earnings, which fell short of analysts' estimates, raising concerns about the company's financial performance. The disappointing results may impact investor confidence and highlight potential challenges in achieving profitability. As APLS continues to navigate its growth strategy, investors will be closely monitoring future developments and guidance to assess the company's trajectory in the competitive pharmaceutical landscape.

Read full article →